EP1064948A2 — Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine
Assigned to Pfizer Products Inc · Expires 2001-01-03 · 25y expired
What this patent protects
The present invention relates to a method of treating migraine in a mammal, including a human, by administering to the mammal a 5HT 1 receptor agonist in combination with caffeine and a cyclooxygenase-2 (COX-2) inhibitor. It also relates to pharmaceutical compositions containing…
USPTO Abstract
The present invention relates to a method of treating migraine in a mammal, including a human, by administering to the mammal a 5HT 1 receptor agonist in combination with caffeine and a cyclooxygenase-2 (COX-2) inhibitor. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a 5HT 1 receptor agonist with caffeine a cyclooxygenase-2 (COX-2) inhibitor.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.